Bringing revolutionary CRISPR-based diagnostics to market

17 May 2021

In this video interview, Tim Patno, Vice President of product development for Mammoth Biosciences, Inc., describes how the company uses the latest CRISPR technology to read and write the code of life.

Through the unprecedented power of CRISPR-Cas systems, Mammoth Biosciences aims to make fast and simple molecular diagnostic solutions more widely available, something that has been made possible through collaboration with Merck. To this end, Dr. Yves Dubaquie, Head of Diagnostics Solutions at Merck, describes how manufacturing expertise and critical raw materials quality and supply is pivotal in ensuring success. 

The Life Science business of Merck  operates as MilliporeSigma in the U.S. and Canada.